KUNMING, China, Dec. 9 /PRNewswire-Asia-FirstCall/ -- China Shenghuo Pharmaceutical Holdings, Inc. (NYSE Alternext US: KUN) ('China Shenghuo' or the 'Company'), today announced that the Company's shares would resume trading on NYSE Alternext US LLC ('NYSE Alternext US' or the 'Exchange') at the open of business on Tuesday, December 9th. The Company's shares will continue to trade under the symbol 'KUN.'

'We are delighted that the Exchange has decided to allow our shares to resume trading,' said Mr. Gui Hua Lan, Chief Executive Officer of China Shenghuo. 'The relisting of our shares marks a major milestone for the Company and it offers a measure of reassurance to both our retail and institutional investors that we have succeeded in putting a very challenging period in the Company's history behind us.'

About China Shenghuo

Founded in 1995, China Shenghuo is a specialty pharmaceutical company that focuses on the research, development, manufacture and marketing of Sanchi- based medicinal and pharmaceutical, nutritional supplement and cosmetic products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd., it owns thirty SFDA (State Food and Drug Administration) approved medicines, including the flagship product Xuesaitong Soft Capsules, which has already been listed in the Insurance Catalogue. At present, China Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine to hospitals and drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to Asian countries such as Indonesia, Russia and Kyrgyzstan. For more information, please visit http://www.shenghuo.com.cn .

Safe Harbor Statement

This press release may contain certain 'forward-looking statements,' as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties.